Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Axi-Cel Plus Atezolizumab Active, Safe in DLBCL

January 13th 2018

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

Cost Effectiveness and Future of CAR T Therapy

January 9th 2018

Evaluating CAR T-Cell Therapy Use

January 9th 2018

Potential for CAR T-Cell Therapy for R/R AML

January 9th 2018

BCMA-Targeted CAR T-Cell Therapy for Myeloma

January 9th 2018

Allogeneic CAR T-Cell Approaches for NHL

January 9th 2018

The Use of CTL019 in Lymphoma

January 9th 2018

JCAR017 for B-Cell NHL

January 9th 2018

Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma

January 9th 2018

Clinical Data for Axi-Cel in Lymphoma

January 9th 2018

FDA Approval for Axi-Cel in NHL

January 9th 2018

Need for Salvage Therapies in R/R NHL

January 9th 2018

Clinical Data Behind CAR T-Cell Therapies in ALL

January 9th 2018

Tisagenlecleucel for Relapsed/Refractory ALL

January 9th 2018

The Promise of CAR T-Cell Therapy for ALL

January 9th 2018

Mechanisms of Resistance for CAR T Therapy

January 9th 2018

Managing CAR T-Cell Therapy Toxicity

January 9th 2018

Practicality of CAR T Therapy

January 9th 2018

The Status of CAR T in Hematologic Malignancies

January 9th 2018

Dr. Martin on Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCL

January 6th 2018

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL).